Can-Fite BioPharma (CANF) Interest Expenses (2014 - 2025)
Can-Fite BioPharma's (CANF) quarterly Interest Expenses came in at $34.1 million in Q4 2025, up 21.5% YoY from $28.1 million in Q4 2024, and up 21.5% on a QoQ basis from $28.1 million in Q4 2024.
Can-Fite BioPharma (CANF) Interest Expenses (2014 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 12 years of Interest Expenses data on file, last reported at $34.1 million in Q4 2025.
- Quarterly Interest Expenses rose 21.5% year-over-year to $34.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.1 million (up 21.5% YoY) and the FY2025 annual result came in at $34.1 million, up 21.5% from the prior year.
- Interest Expenses advanced to $34.1 million in Q4 2025, from $28.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $34.1 million in Q4 2025 to a low of $973000.0 in Q2 2023.
- A 5-year average of $19.5 million and a median of $26.6 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses tumbled 97.27% — and 2022, when it jumped 2605.41%.
- Tracing CANF's Interest Expenses over 5 years: stood at $980000.0 in 2021, then jumped by 2605.41% to $26.5 million in 2022, then grew by 0.56% to $26.7 million in 2023, then rose by 5.24% to $28.1 million in 2024, then gained by 21.5% to $34.1 million in 2025.
- The last three Interest Expenses figures came in at $34.1 million (Q4 2025), $28.1 million (Q4 2024), and $26.7 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.09 Mn |
| Dec 31, 2025 | 34.09 Mn |
| Dec 31, 2024 | 28.06 Mn |
| Dec 31, 2024 | 28.06 Mn |
| Dec 31, 2023 | 26.66 Mn |
| Dec 31, 2023 | 26.66 Mn |
| Jun 30, 2023 | 973,000.00 |
| Jun 30, 2023 | 973,000.00 |
| Dec 31, 2022 | 26.51 Mn |
| Dec 31, 2022 | 26.51 Mn |
| Dec 31, 2021 | 980,000.00 |
| Dec 31, 2021 | 980,000.00 |
| Dec 31, 2020 | 35.89 Mn |
| Dec 31, 2020 | 35.89 Mn |
| Dec 31, 2019 | 537,000.00 |
| Dec 31, 2019 | 537,000.00 |
| Sep 30, 2019 | -519,000.00 |
| Sep 30, 2019 | -519,000.00 |
| Jun 30, 2019 | -119,000.00 |
| Jun 30, 2019 | -119,000.00 |